Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition containing uretic, statin and folic acid as well as applications thereof

A composition and drug technology, applied in the direction of drug combination, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve the problems of undiscovered diuretics, statin lipid-lowering drugs and folic acid combination, and achieve synergistic protection of endothelium Effect of cell function, reduction effect, effect of strengthening stiffness

Active Publication Date: 2013-03-27
SHENZHEN AUSA PHARM CO LTD +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] There is no report on the combination of diuretics, statin lipid-lowering drugs and folic acid in clinical and existing research. Based on the above considerations, we conducted a study on the combined application of diuretics, statin lipid-lowering drugs and folic acid. satisfactory results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing uretic, statin and folic acid as well as applications thereof
  • Pharmaceutical composition containing uretic, statin and folic acid as well as applications thereof
  • Pharmaceutical composition containing uretic, statin and folic acid as well as applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Target organ protection effect of hydrochlorothiazide + atorvastatin + folic acid on hypertensive rats with dyslipidemia

[0045] 1. Preparation of compound model animals

[0046] For SD rats, the experiment was started after 5 days of adaptive feeding. Two kidneys and one clip operation were performed to prepare 2K1C hypertensive model animals. After feeding for 6 weeks, measure the blood pressure of the rats (measuring three times to get the average value). If the blood pressure > 140mmHg, the model is considered successful, and the model group begins to gavage fat emulsion (cholesterol 10g, propylene glycol 20ml, bile salt 2g, Tween-8020ml) every day. , propylthiouracil 1g, peanut oil 20ml, sucrose 20g, after dissolving, add distilled water to 200ml) 10ml / kg and free drinking water (containing 1% methionine), after 4 weeks of intragastric administration of fat emulsion (retest once after 2 weeks of infusion of fat emulsion) Blood pressure) The rats were ...

Embodiment 2

[0081] Example 2: Target organ protection effect of indapamide + simvastatin + folic acid on hypertensive rats with dyslipidemia

[0082] 1. Preparation of compound model animals

[0083] For SD rats, the experiment was started after 5 days of adaptive feeding. Two kidneys and one clip operation were performed to prepare 2K1C hypertensive model animals. After feeding for 6 weeks, measure the blood pressure of the rats (measuring three times to get the average value). If the blood pressure > 140mmHg, the model is considered successful, and the model group begins to gavage fat emulsion (cholesterol 10g, propylene glycol 20ml, bile salt 2g, Tween-8020ml) every day. , propylthiouracil 1g, peanut oil 20ml, sucrose 20g, after dissolving, add distilled water to 200ml) 10ml / kg and free drinking water (containing 1% methionine), after 4 weeks of intragastric administration of fat emulsion (retest once after 2 weeks of infusion of fat emulsion) Blood pressure) The rats were fasted for...

Embodiment 3

[0120] Example 3: Target organ protection effect of spironolactone + pitavastatin + folic acid on hypertensive rats with dyslipidemia

[0121] 1. Preparation of compound model animals

[0122]For SD rats, the experiment was started after 5 days of adaptive feeding. Two kidneys and one clip operation were performed to prepare 2K1C hypertensive model animals. After feeding for 6 weeks, the blood pressure of the rats was measured (measured three times to get the average value). If the blood pressure > 140mmHg, the model was considered successful, and the model group began to gavage fat emulsion (cholesterol 10g, propylene glycol 20ml, bile salt 2g, Tween-80 20ml, 1g of propylthiouracil, 20ml of peanut oil, 20g of sucrose, after dissolving, add distilled water to 200ml) 10ml / kg and free drinking water (containing 1% methionine), after 4 weeks of intragastric administration of fat emulsion (retest after 2 weeks of infusion of fat emulsion) One blood pressure) The rats were fasted...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing uretic, statin lipid-lowering drugs and folic acid compound. The pharmaceutical composition contains medicinal dose of uretic, medicinal dose of statin lipid-lowering drugs, medicinal dose of folic acid compound and a carrier acceptable in pharmaceutics. The invention also relates to an application of the pharmaceutical composition in preparing medicines for preventing and treating or retarding high blood pressure accompanied by dyslipidemia and the application thereof in preparing medicines for treating target organ damage caused by the high blood pressure accompanied by dyslipidemia; in addition, the invention further relates to the application of the pharmaceutical composition in preparing medicines for lowering risk of cardiovascular and cerebrovascular events caused by high blood pressure accompanied by dyslipidemia. The invention belongs to the pharmaceutical field. With the implementation of the invention, the pharmaceutical composition with special usage, provided to the patients, can improve compliance of the patients, bring convenience to the patients to take medicines and reduce medical expenses, thus enjoying good market prospect.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing diuretics, statin lipid-lowering drugs and folic acid, and the use of the pharmaceutical composition in the preparation of drugs for preventing, treating or delaying hypertension with dyslipidemia and hypertension with blood lipids The use of the drug for target organ damage caused by abnormality, the invention also relates to the use of the pharmaceutical composition in the preparation of a drug for reducing the risk of cardiovascular and cerebrovascular events caused by hypertension and dyslipidemia. belongs to the field of pharmacy. Background technique [0002] Cardiovascular disease is one of the main causes of human death, mainly coronary heart disease and stroke. Three major risk factors for cardiovascular disease have been identified: dyslipidemia, including high low-density lipoprotein cholesterol (LDL-C), high triglycerides, and low high-density lipoprotein cholesterol (HDL-C);...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61P9/12A61P3/06
Inventor 陈明侠王文艳陈光亮徐希平
Owner SHENZHEN AUSA PHARM CO LTD